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Objective: Prostate cancer (PC) is one of the most common cancer and an important reason of cancer
speciﬁc death. The incidence of patients who diagnosed at low stage increased because of widespread
using Prostate Speciﬁc Antigen (PSA) testing. We evaluated the patients who were diagnosed single
microscopic focus of adenocarcinoma and treated radical prostatectomy at ﬁnal pathology.
Methods: The patients who underwent transrectal ultrasound guided prostate biopsy between January
2004 and January 2012 were enrolled retrospectively. We extracted the patients who were diagnosed
single microscopic focus of adenocarcinoma and treated with RP. Single microscopic adenocarcinoma
was deﬁned as one single focus measuring 3 mm or less, well differentiated (Gleason 6) adenocarci-
noma. 37 patients were included at the study. Clinical data; including age, serum PSA levels, PSA density
and prior biopsy and prostatectomy specimen results were recorded. In pathological examination; high
molecular weight cytokeratin (HMW-CK), p63, and alpha-methylacyl-CoA racemase (AMACR) were used
for differential diagnosis.
Results: The patients' ages were between 42 and 77 with a mean age of 64.9 ± 7.57 years. Mean PSA
levels and prostate volumes were 8.03 ± 5.21 ng/ml and 54 ± 25.51 cc. T0, T2a, T2c and T3a were re-
ported in 2 patients, 17 patients, 17 patients and 1 patient after pathological evaluation. According to the
Gleason grading system; 6 patients were 7 (3 + 4), one patient was 7 (4 + 3), one patient was 5 (3 + 2) and
27 patients were 6 (3 + 3).
Conclusion: Small volume of cancer at prostate biopsy is not necessarily small cancer in radical pros-
tatectomy. The treatment choice may be over or under treatment for some patients, so the patients must
be informed when choosing the treatment.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The widespread use of prostate speciﬁc antigen (PSA) screening
and aggressive prostate biopsy protocols have increased the inci-
dence of small volume organ conﬁned prostate tumors.1 Although
30e40% of men older than 50 years have prostate cancer, only 8% of
the cancers are clinically signiﬁcant.2 The Epstein criteria are the
most frequently used criteria for deﬁning whether prostate cancer
is clinically signiﬁcant or not.3 Epstein criteria consists of: (1) a
Gleason score 6; (2) fewer than three positive cores; (3) PSA
density 0.15 ng/mL; and (4) < 50% of cancer involvement in any
core.4 However, there is no clear consensus for managing singleok, Number 2, Çorum, Turkey.
an).
ciﬁc Prostate Society, Published bmicroscopic focus of adenocarcinoma at prostate biopsy. This is
because small volume of cancer at biopsy is not necessarily small
cancer in radical prostatectomy (RP) specimens.1
We evaluated patients who were diagnosed with single micro-
scopic focus of adenocarcinoma at prostate biopsy and who were
treated with RP at our department.
2. Materials and methods
The patients (2,425 cases) who underwent transrectal ultra-
sound guided prostate biopsy between January 2004 and January
2012 were enrolled retrospectively. We extracted the data on pa-
tients who were diagnosed with single microscopic focus of
adenocarcinoma and who were treated with RP. Single microscopic
adenocarcinoma was deﬁned as one single focus measuring 
3 mm and well differentiated (Gleason 6). Clinical data including
age, serum PSA levels, PSA density, (dividing PSA by the weight ofy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Clinical data of the patients treated with radical prostatectomy.
Mean± SD Range
Age (y) 64.9± 7.57 42e77
PSA (ng/mL) 8.03± 5.21 1.4e38.6
PSA density 0.15± 0.09 0.04e0.51
Prostate volume (cc) 54± 25.51 20e140
Tumor volume (cm3) 2.11± 2.33 0e10
PSA, prostate speciﬁc antigen; SD, standard deviation.
Table 3






Data are presented as n (%).
Çalıs¸kan et al / Microscopic focus of prostate adenocarcinoma 133prostate at RP), and prior biopsies were noted. In pathological ex-
amination, immunohistochemical studies were performed with
high molecular weight cytokeratin, p63, and alpha-methylacyl-CoA
racemase (AMACR). The RP specimens were sectioned and entirely
embedded using 5 mm thick blocks. The tumors were graded ac-
cording to the Gleason system and staged using TNM classiﬁcation.
The tumor volume in the RP specimens was calculated. Criteria for
diagnosing insigniﬁcant prostate cancer (IPCa) were a tumor vol-
ume < 0.5 cm3, Gleason score < 7, and organ conﬁned disease at RP
specimen deﬁned by Epstein criteria.4
3. Results
Sixty patients had microscopic adenocarcinoma on needle
prostate biopsy, accounting for 2.4% of 2,425 cases. The incidence of
prostate cancer diagnosed with prostate biopsy is 7.1% in our study.
The patients whowere diagnosed with microscopic prostate cancer
and treated with RP were included in the study (37 patients). Pa-
tients were aged 42e77 years with a mean age of 64.9± 7.57 years.
The number of prostate cores was between six and 18, with a
median number of 8.3± 2.26. Table 1 lists the patient characteris-
tics and clinical data of the patients. Prior prostate biopsies were
present in seven patients, four patients had atypical acinar prolif-
eration, and the others were benign prostate hyperplasia (BPH).
Immunohistochemical studies with high molecular weight cyto-
keratin, p63, and AMACR were performed in 24 of the 60 patients
(Table 2). Localization of cancers were reported: 20 from apex, 15
from base, 20 from mid zone, and ﬁve from transition zone of the
prostate.
Treatments used on these patients were active surveillance,
radiotherapy, RP, orchiectomy, and maximal androgen deprivation
therapy. Active surveillance was used for 15 patients and three
patients were treated with radiotherapy. Surgical orchiectomy was
performed in one patient and 37 patients were treated with RP. In
the active surveillance group, three patients had undergone pros-
tate biopsy, two of these patients were reported BPH, and one pa-
tient was reported ASAP. In the second biopsy, after six months,
BPH was reported.
At RP, six patients had a Gleason score of 7 (3þ 4), one patient
had a Gleason score of 7 (4þ 3), and one patient had a Gleason
score of 5 (3þ 2). The other 27 patients had a Gleason score of 6
(3þ 3). The pathological stage of the patients are shown in Table 3.
IPCa was present in seven (18.9%) patients at ﬁnal pathology. A
tumor was not found in two patients’ (5.4%) RP specimens. One
patient had local advanced prostate cancer that was reported asTable 2
Immunohistochemical studies of the patients for differential diagnosis.
AMACR p63 HMW-CK 34BE12
Positive 14 e e e
Negative e 19 16 2
AMACR, alpha-methylacyl-CoA racemase; HMW-CK, high-molecular weight
cytokeratin.T3a. Clinically signiﬁcant prostate cancer was determined in 75.6%
of the patients at ﬁnal pathology.
4. Discussion
The widespread use of PSA testing with extensive transrectal
ultrasound prostate biopsy protocols with lower PSA thresholds
have resulted in an increase of low volume (< 0.2e0.5 mL) prostate
cancers.5 Single microscopic focus of low grade prostate cancer at
prostate biopsy is not associated with patients that have clinically
insigniﬁcant disease on ﬁnal RP specimens.6 These cancers cause
little harm during the patient’s lifetime, but overdiagnosis can
potentially lead to overtreatment, which accounts for 40e50% on
the European Screening Program.7
Several authors have compared specimen and biopsy tumor
characteristics for determining the indolent prostate cancer.5 Terris
et al8 considered that one single positive biopsy containing a focus
of 3mmwell differentiated prostate cancer (Gleason score 6) is
predictive of IPCa. Epstein criteria consists of less than three posi-
tive cores containing < 50% of well differentiated prostate cancer
and PSA density lower than 0.15.4 Bocon-Gibod et al5 reported that
29% of patients had IPCa of 56 patients with one single focus of <
3 mm. On the contrary, Allan et al9 analyzed 54 patients with one
single neoplastic focus of 0.5 mm in length of biopsy, and 67% of the
patients were IPCa at RP specimens. Thorsan et al10 reported that
patients with minimal adenocarcinoma on needle biopsy was
deﬁned as less than 1 mm linear extent, but only 18% of had IPCa at
RP specimens. In another study, patients with a minute focus of
carcinoma of  5 mm on needle biopsy, 13.85% of the patients had
Stage 3 carcinoma and only 17.25% of patients had clinically insig-
niﬁcant cancer at RP specimens.11 In our study, 18.9% of the patients
had IPCa at ﬁnal pathology.
Gleason score concordance range in the biopsy and RP speci-
mens is between 28% when using sextant biopsy and 72% with
more extended biopsy protocols.1 Sheridan et al12 reported that
men who were undergoing active surveillance were at 19% risk for
upgrading on subsequent biopsies. Most of the tumors were
upgraded within 2 years of the initial diagnosis because the higher
grade tumor was not sampled in the biopsy. The presence of a
Gleason score of 7 on biopsy is signiﬁcant cancer and warrants
active therapy such as surgery or radiotherapy.9 In this study,
Gleason scores of 6 and 7 accounts for 72.9% and 18.91% of the
patients, respectively.
T0 means an absent primitive tumor in a specimen according to
the 2002 TNM classiﬁcation for prostate cancer.13 T0 has been
noted after prostate surgery, biopsy, and hormonal treatment. The
prevalence is 2.25e15% of RP specimens after neoadjuvant hor-
monal therapy. Di Giusseppe et al14 reported that tumors < 0.1 cc as
minute and 0.03 cc tumors as difﬁcult to ﬁnd, Goldstein et al15
deﬁned a mean 0.0199 cc tumor volume. The incidence of T0 is
5.4% of present study.
Treatment of limited adenocarcinoma of a Gleason score of 
6 at prostate biopsy is a dilemma of whether to subject patients
to deﬁnitive therapy such as RP.11 RP is a very aggressive
Prostate Int 3 (2015) 132e134134treatment for these patients.1 PSA screening has resulted in
overdiagnosis and overtreatment of prostate cancer, with the
majority of prostate cancer likely to be clinically insigniﬁcant.16
To reduce overtreatment and overdiagnosis, active surveillance
was introduced. Active surveillance includes closely monitoring a
patient with regular follow-up PSA, prostate biopsy, and digital
rectal examination. If progression of the disease is detected by
any of these monitoring measures, curative therapy should be
considered.
There is no consensus about a predictive model for IPCa.1
Epstein criteria was deﬁned in 1994 and is the most common
used for determining IPCa.16 The overall predictability for IPCa fell
from 84% to 37e76% after 2005. A microfocus adenocarcinoma
Gleason score 6 has a risk of upgrading and upstaging to pT3 in 18%
and 8% of patients at ﬁnal pathology.6
The underdiagnosis of limited prostate adenocarcinoma on
needle biopsy is a frequent problem in prostate pathology.17
Immunohistochemistry may be useful for diagnosis of limited
adenocarcinoma of the prostate. Basal cell markers, such as high
molecular weight and p63, are found in benign glands and absent
in adenocarcinoma of the prostate. AMACR is a cytoplasmis protein,
is known as P504S, and has been recognized as a tumormarker. The
majority of the prostate cancers (80e100%) have positive staining
for AMACR.
Our study has several limitations. This study includes a small
number of patients and is retrospective. The patients were not
treated by a single surgeon and evaluated by a single pathologist.
Further studies are needed for deﬁning the clinical importance of
microscopic adenocarcinoma of the prostate.
In conclusion, the presence of microscopic prostate adenocar-
cinoma at prostate biopsy corresponds to clinically signiﬁcant in
75.6% of patients.While two patients had no tumor, one patient had
advanced stage at ﬁnal pathology.
Clinicians should consider that RP can be overtreatment for
some patients. The patients who were diagnosed with single
microscopic prostate cancer must be evaluated carefully and all of
the treatment modalities must be discussed with the patients.
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